ES2284056T3 - Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil. - Google Patents

Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil. Download PDF

Info

Publication number
ES2284056T3
ES2284056T3 ES04779540T ES04779540T ES2284056T3 ES 2284056 T3 ES2284056 T3 ES 2284056T3 ES 04779540 T ES04779540 T ES 04779540T ES 04779540 T ES04779540 T ES 04779540T ES 2284056 T3 ES2284056 T3 ES 2284056T3
Authority
ES
Spain
Prior art keywords
compound
disorder
pharmaceutically acceptable
solvate
ester
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES04779540T
Other languages
English (en)
Spanish (es)
Inventor
Anima Ghosal
Wei Tong
Swapan K. Chowdhury
Shmuel Zbaida
Mark A. Wirth
Kevin B. Alton
James E. Patrick
Craig D. Boyle
Andrew Stamford
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme LLC
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Application granted granted Critical
Publication of ES2284056T3 publication Critical patent/ES2284056T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Transplantation (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Vascular Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES04779540T 2003-07-31 2004-07-29 Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil. Expired - Lifetime ES2284056T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49221803P 2003-07-31 2003-07-31
US492218P 2003-07-31

Publications (1)

Publication Number Publication Date
ES2284056T3 true ES2284056T3 (es) 2007-11-01

Family

ID=34115611

Family Applications (1)

Application Number Title Priority Date Filing Date
ES04779540T Expired - Lifetime ES2284056T3 (es) 2003-07-31 2004-07-29 Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.

Country Status (10)

Country Link
US (1) US7312223B2 (enExample)
EP (1) EP1648895B1 (enExample)
JP (1) JP2007500714A (enExample)
CN (1) CN1860119A (enExample)
AT (1) ATE363483T1 (enExample)
CA (1) CA2533715A1 (enExample)
DE (1) DE602004006756T2 (enExample)
ES (1) ES2284056T3 (enExample)
MX (1) MXPA06001195A (enExample)
WO (1) WO2005012303A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60307628T2 (de) * 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen
WO2006023603A2 (en) * 2004-08-17 2006-03-02 The Johns Hopkins University Pde5 inhibitor compositions and methods for treating cardiac indications
KR20090087795A (ko) * 2008-02-13 2009-08-18 한양대학교 산학협력단 혈관 재협착 예방 및 치료를 위한 약학 조성물 및 이를포함하는 스텐트
CN101747282A (zh) 2008-12-10 2010-06-23 上海特化医药科技有限公司 一类含有嘧啶酮苯基的化合物、其药物组合物及其制备方法和用途
US20100261737A1 (en) * 2009-04-10 2010-10-14 Medtronic Vascular, Inc. Method of Treating Erectile Dysfunction
WO2013024022A1 (en) 2011-08-12 2013-02-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary hypertension
US20140328893A1 (en) 2011-10-11 2014-11-06 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nutlin compounds for use in the treatment of pulmonary hypertension
CN106770618A (zh) * 2015-11-20 2017-05-31 中国康复研究中心 一种建立急性缺血性脑卒中特征蛋白的质谱模型的方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8906792D0 (en) * 1989-03-23 1989-05-10 Beecham Wuelfing Gmbh & Co Kg Treatment and compounds
IL98559A0 (en) 1990-06-21 1992-07-15 Schering Corp Polycyclic guanine derivatives
GB9020959D0 (en) * 1990-09-26 1990-11-07 Beecham Group Plc Novel compounds
US5409934A (en) * 1990-12-21 1995-04-25 Smith; David G. Xanthine derivatives
GB9210839D0 (en) * 1992-05-21 1992-07-08 Smithkline Beecham Plc Novel compounds
HUT72640A (en) 1993-02-26 1996-05-28 Schering Corp 2-benzyl-polycyclic guanine derivatives, pharmaceutical compositions containing them and process for preparing them
US6821978B2 (en) * 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
PE20040538A1 (es) 2002-05-31 2004-08-30 Schering Corp Polimorfos inhibidores de xantina fosfodiesterasa v
DE60307628T2 (de) 2002-05-31 2007-08-09 Schering Corporation Verfahren zur herstellung von xanthin phosphodiesterase v inhibitoren und deren vorstufen

Also Published As

Publication number Publication date
DE602004006756T2 (de) 2008-01-24
JP2007500714A (ja) 2007-01-18
EP1648895B1 (en) 2007-05-30
CA2533715A1 (en) 2005-02-10
EP1648895A1 (en) 2006-04-26
WO2005012303A1 (en) 2005-02-10
HK1082739A1 (en) 2006-06-16
DE602004006756D1 (de) 2007-07-12
US20050026939A1 (en) 2005-02-03
CN1860119A (zh) 2006-11-08
ATE363483T1 (de) 2007-06-15
MXPA06001195A (es) 2006-04-11
US7312223B2 (en) 2007-12-25

Similar Documents

Publication Publication Date Title
ES2222614T3 (es) Derivados de purina y medicina que los contiene como ingrediente activo.
ES2208310T3 (es) Derivados de pirimido(6,1-a) isoquinolin-4-ona.
EP4328224A1 (en) Parp inhibitor containing piperazine structure, preparation method therefor and pharmaceutical use thereof
ES2936827T3 (es) Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
TWI265031B (en) Novel pharmaceuticals
ES2222389T3 (es) Derivados de 6-fenilpirrolopirimidindiona.
JP4540337B2 (ja) 新規４−アミノフロピリミジン化合物およびそれらの使用
ES2284056T3 (es) Metabolito de inhibidor de fosfodiesterasa 5 de xantina y sus derivados, utiles para el tratamiento de la disfuncion erectil.
CN111655693B (zh) 抑制瞬时型感受器电位a1离子通道
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
JP2010505747A (ja) Ａ２ａアデノシンレセプタの選択的アンタゴニスト
ES2220109T3 (es) 5-heterociclilpirazolo (4,3-d) pirimidin-7-onas para el tratamiento de la disfuncion erectil masculina.
JP2023517541A (ja) 不整脈の治療のためのニコチンアミドモノヌクレオチド誘導体
US11427590B2 (en) Small molecule inhibitors of neutral sphingomyelinase 2 (nSMase2) for the treatment of neurodegenerative diseases
ES2353848T3 (es) Derivados de quinazolina útiles para el tratamiento de la enfermedad arterial periférica y como inhibidores de fosfodiesterasa.
CN115109058B (zh) 一种用于治疗胃癌的药物及其制备方法
CN115768775B (zh) Idh突变体抑制剂及其用途
ES2315898T3 (es) Derivados de carbamato de 2h- o 3h-benzo(e)inzadol-1-ilo, su preparacion y su aplicacion en terapeutica.
ES2292621T3 (es) Derivados de pirrolotriazolopirimidinona.
ES2261940T3 (es) Derivados de 3-hetoeroaril-3,5-dihidro-4-oxo-4hpiridazino-(4,5-b)-indol-1-acetamida, su preparacion y su aplicacion en terapeutica.
EP2578588A1 (en) Novel 1,4-diazepam pde-5 inhibitor derivatives
CN116217567B (zh) 烃基取代的α-咔啉类似物或其药用盐、其药物组合物及其制备方法和用途
EP4269417A1 (en) Polysubstituted imidazole[4,5-c][1,2]thiazine derivative and use thereof
TW202540096A (zh) 靶向降解雄激素受體的雙功能嵌合體的雜環化合物及其用途
HK1082739B (en) Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction